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Magnetic resonance spectroscopy and brain volumetry in Mild Cognitive 
Impairment. A prospective study. 
ABSTRACT 
OBJECTIVE: To assess the accuracy of magnetic resonance spectroscopy (1H-
MRS) and brain volumetry in  mild cognitive impairment (MCI) to predict 
conversion to probable Alzheimer’s disease (AD).  
METHODS: Forty-eight patients fulfilling the criteria of amnestic MCI who 
underwent a conventional magnetic resonance imaging (MRI) followed by 
MRS, and T1-3D on 1.5 Tesla MR unit. At baseline the patients underwent 
neuropsychological examination. 1H-MRS of the brain was carried out by 
exploring the left medial occipital lobe and ventral posterior cingulated cortex 
(vPCC) using the LCModel software. A high resolution T1-3D sequence was 
acquired to carry out the volumetric measurement. A cortical and subcortical 
parcellation strategy was used to obtain the volumes of each area within the 
brain. The patients were followed up to detect conversion to probable AD.  
RESULTS: After a 3-year follow-up, 15 (31.2%) patients converted to AD. The 
myo-inositol in the occipital cortex and glutamate+glutamine (Glx) in the 
posterior cingulate cortex predicted conversion to probable AD at 46.1% 
sensitivity and 90.6% specificity. The positive predictive value was 66.7%, and 
the negative predictive value was 80.6%, with an overall cross-validated 
classification accuracy of 77.8%. The volume of the third ventricle, the total 
white matter and entorhinal cortex predict conversion to probable AD at 46.7% 
sensitivity and 90.9% specificity. The positive predictive value was 70%, and the 
negative predictive value was 78.9%, with an overall cross-validated 
classification accuracy of 77.1%. Combining volumetric measures in addition to 
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the MRS measures the prediction to probable AD has a 38.5% sensitivity and 
87.5% specificity, with a positive predictive value of 55.6%, a negative 
predictive value of 77.8% and an overall accuracy of 73.3%.  
 
CONCLUSION: Either MRS or brain volumetric measures are markers 
separately of cognitive decline and may serve as a noninvasive tool to monitor 
cognitive changes and progression to dementia in patients with amnestic MCI, 
but the results do not support the routine use in the clinical settings. 
 
Key words: Mild cognitive impairment; Alzheimer’s disease; Magnetic 
resonance spectroscopy; Brain volumetry 
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INTRODUCTION 
The amnestic subtype of MCI (Mild cognitive impairment)  is usually caused by 
a degenerative etiology, and most frequently represents a prodromal stage of 
AD (Alzheimer's disease).  Form an epidemiologic perspective, the rates of 
progression to AD range from 6 to 10% per year but in the referral clinical 
setting the rates are higher (10-15% per year)[1] . The definitive diagnosis of AD 
can only be based on the combination of symptoms plus histopathology, with 
the presence of large number of neuritic plaques and neurofibrillary tangles in 
brain tissues[2]. The search for noninvasive diagnostic methods has been of 
considerable interest, because, apart from allowing detection of those who 
develop AD, they will serve to monitor changes and assess the effects of drugs 
in AD [3]. 
Atrophy of the  hippocampus, and entorhinal cortex as well, are frequent 
prodromal signs of AD in subjects with MCI[4-8] . Whole brain, cortical, and 
ventricular volumes have also shown  to be associated  with progression to AD, 
although the volume measurements from MR images have relatively low 
accuracy in the prediction of AD[9-12] . 
Proton magnetic resonance spectroscopy (1H-MRS) is one of the 
techniques used to assess potential disruptions of neuronal integrity and 
associated neurochemical dysregulations. MRS provides additional biochemical 
information, which can be useful to determine the clinical stratification for a 
specific patient. Myo-Inositol (mI) is considered a glial marker, and as a 
possible degradation product of myelin and osmolyte or regulator of cell 
volume. Choline (Cho) is a constituent of phospholipids metabolism of cell 
membranes and reflects cell proliferation. Creatine (Cr) plays an important role 
in brain energy system (ATP), a marker of brain metabolism. The N-
acetylaspartate (NAA) is a marker of neuronal and axonal density and 
mitochondrial functioning. Glutamate (Glu) is the primary excitatory 
neurotransmitter in the brain. Studies have shown that the ratio of N-
acetylaspartate/creatine can predict with high accuracy  conversion from MCI 
to AD [13-15] . Also increased mI/Cr and decreased NAA/Cr ratios correlated 
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well with the severity of AD [16]. Hitherto studies suggest that MRS combined 
with measurements of brain volumes can provide neuroimaging markers of 
disease progression .  
The purpose of this study is to explore whether the changes in brain 
volumes and metabolite levels are associated with cognitive decline and the 
development of dementia in amnestic-MCI patients over time. We hypothesize 
that MRS and brain volumetry can be useful predictors  of cognitive 
deterioration in amnestic- MCI patients. 
 
PATIENTS AND METHODS  
 The initial cohort was composed of 52 patients with amnestic MCI who 
were followed for a mean period of 3 years (standard deviation [SD]: 6.7 
months). However, 4 subjects were discarded due to problems of movement or 
processing. Therefore, 48 patients (30 female and 18 male) with amnestic MCI 
were finally included in the study. All of them underwent a MRI brain 
volumetry assessment, MRS and clinical examination at baseline were included 
in a longitudinal study. Table 1 lists the main baseline demographic variables 
and the results of memory tests and scales. The mean age of the cohort was 74.4 
years (SD: 6.9). The mean age was 73.7 (SD 7.1) years in women and 75.2 (SD 
6.7) years in men. After a mean follow-up of 36 months, 15 (31.2%) patients out 
of 48 converted to probable AD according to the NINCDS-ADRDA group 
criteria, and none of them reverted to normality. There were 9 women and 6 
male in the group of converters and 21 women and 12 male in the group of non-
converters. Age did not differ significantly by gender (F=0.51, p=0.476), but 
converters were significantly older than non-converters (mean age: 78 (SD 5.5) 
years for converters vs 75 (SD 4.6) years for non-converters (F=8.34; P=0.006). 
No differences were seen in the male/female ratio proportion (Chi-Square, 
p=0.528), Sex has a significant effect on the volume of the white (F= 29.79; P= 
<0.001) and gray matter (F=28.14; P <0.001) (males have significant larger 
volumes in comparison with females). Age has a significant (negative) 
correlation with the total amount of gray matter. (r Pearson = -0.40, p = 0.005).  
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Conversion to dementia of probable Alzheimer type was based on the 
criteria of the National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA) group criteria [17] . Informed consent was obtained from the 
participants before their inclusion in the study. The study protocol was 
approved by the ethical review board of the regional health authority. 
 
Neuropsychological examination. 
 
 The patients include here were referred by general practitioners because 
of memory complaints which were corroborated by relatives or caregivers. The  
were first screened for memory impairment with the Memory Impairment 
Screen (MIS) [18], a simple delayed recall test. At baseline, the patients 
underwent the following neuropsychological examination: the Mini-Mental test 
(Spanish version with a maximum possible score of 35 points) [19], the Blessed 
Dementia Rating Scale, the clock drawing test, the Geriatric Depression Scale 
and the Rey Auditory Verbal Learning Test (RAVLT) delayed recall. The 
patients included in this study must score 5 or lower in the MIS, 0.5 in the CDR 
and a score in the Mini-Mental higher than 21 points. The cut-off points for the 
RAVLT 20 min delayed recall were as follows: ≤4 for patients aged up to 69 and 
≤3 for patients aged 70 and older. Those with depressive symptoms ( 11 points 
or higher in the Geriatric Depression Scale) were re-evaluated after 
antidepressant treatment. 
 
Magnetic Resonance Imaging.  
 
MRI was performed on all patients. For the volumetric measurements, a three 
dimensional (3D) high-resolution whole-brain gradient-echo T1-weighted 
sequence was obtained on a 1.5 Tesla system (Signa HD, 12.x scanner; General 
Electric Medical Systems, Milwaukee, WI) using an 8-channel head coil. The 
acquisition protocol included the following parameters: 122 coronal slices, TR = 
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9.05 ms, TE = 1.72 ms, 1.5 mm slice thickness with no inter-slice gap, acquisition 
matrix = 256 x 256, flip angle = 20º and voxel size = 0.86 x 0.86 x 1.5 mm. After 
acquisition, all images were reviewed by a radiologist and a computer engineer, 
who were blind to clinical subgroups, in order to ensure data quality.  
Additionally, a T1 axial, a T1 sagittal, a T2 and a fluid-attenuated inversion 
recovery sequences were also acquired with clinical purposes. 
Magnetic Resonance Spectroscopy. 
For the quantitative regional analysis, a sagittal and axial T1 and axial 
T2-weighted image was used to locate a voxel or volume of interest (2 x 2 x 2 
cm). These areas of exploration were the left medial occipital lobe and 
posteriomedial parietal cortex. (Figs. 1A and 1b). 1H-MRS was performed using 
a short echo time of 35 milliseconds and a repetition time of 2000 milliseconds, 
and 128 accumulations were gathered using a single-voxel stimulated- echo 
acquisition-mode localization sequence with a spin-echo technique of selective 
excitation with and water suppression. The mode of spectral acquisition was 
probe-p (PRESS technique).  The pure metabolite signal was spoiled, zero-filled, 
and Fourier transformed to produce a spectrum, scaled, drawn onto a 512-by-
512 image, and stored as an image in the system database. Every spectrum was 
automatically fitted to four peaks corresponding to levels of N-acetyl-aspartate 
(NAA), 2.02 ppm; total creatine (Cr), 3.03 ppm; choline-containing compounds 
(Ch), 3.23 ppm; glutamate + glutamine (Glx), 2.1 to 2.55 ppm, and myo-Inositol 
(mI), 3.56 ppm. We also obtained the peak amplitude of the metabolites relative 
to Creatine. For this purpose we used the algorithms provided by the 
manufacturer with the following steps: 1. Setting a global frequency fit parameter. 
2. Performing line width and line shape enhancement by appropriate apodization of
the time domain signal. 3. Fourier transformation of the signal to the appropriate 
frequency resolution and number of points. 4. Calculation of a baseline correction from 
the frequency domain signal. 5. Curve fitting the desired regions of the frequency 
domain signal. 
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 The postprocessing of data was done with the LCModel software, 
version 6.2-0 [20]. Concentration values were not corrected for contributions by 
cerebrospinal fluid or for small reductions in the numeric values because of 
residual T1 and T2 relaxation effects. 
 We also obtained the ratios of the metabolites relative to Cr. Spectra 
were rejected and repeated in the following cases: line width >10 Hz, line shape 
asymmetrical after eddy current correction and the presence of artifacts. Data 
fits with % SD >20 from the Cramér-Rao inequality were eliminated. 
Both areas we examined showed excellent reproducibility in two 
previous studies of test-retest reliability carried out with the same clinical 
scanner in AD patients [21,22]. For the NAA/Cr ratios, the α (the interclass 
correlation coefficient) value was 0.93 and 0.95 in the posteromedial bilateral 
parietal lobe respectively, and 0.89 and 0.87 in the left medial occipital lobe.  
 
Brain Volumetry.  
 
 The T1-3D images were used for the assessment of the brain volumes. 
After the qualitative quality control of the acquired images, they were blinded 
and sent to a workstation for analysis and post-processing. Before performing 
the volumetric measurements, all images were improved using a combination 
of two  spatial filters. First, a non-local filter [23] was applied to minimize the 
random fluctuation of the MR signal due to the thermal noise. This is especially 
relevant when semiautomatic quantitative measurements are being considered. 
The resulting volumes showed a significant higher signal-to-noise ratio when 
compared with the original data. Then, images were also corrected for intensity 
heterogeneities which are usually present in MR images and depend on the 
sensitivity of the coils. A non-parametric method based on the minimization of 
an entropy-related function cost [24] was applied on each image to produce a 
non-biased corrected volume. 
The Freesurfer software package (http://surfer.nmr.mgh.harvard.edu/) 
was used to perform the parcellation and the volumetric measurement of the 
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different brain areas. The method included several steps to extract white and 
gray matter surfaces and to compute the volume of cortical and subcortical 
areas segmented to allow labeling and identifying the regions. These areas were 
labelled defining a minimization cost function based on a combination of the 
probabilistic template location, image intensities and local relationships 
between cortical and subcortical regions. For the purposes of this study we 
included volumes from the following structures: total gray matter, total white 
matter, frontal lobe, temporal lobe, parietal lobe, occipital lobe, lateral 
ventricles, third ventricle, fourth ventricle, hippocampus, globus pallidus, 
amygdala, thalamus, caudate nucleus, putamen, and cerebellum. All these 
structures were independently analyzed  bilaterally (right and left). The 
anatomic accuracy of the gray and white matter parcellation was checked 
qualitatively by a trained neuroradiologist and a computer engineer in order to 
detect faults in the segmentation process. Four subjects were  excluded from the 
initial sample due to misregistration artifacts in the temporal lobe region only 
for volumetry purposes. 
 
Clinical follow-up 
The patients were followed up and re-evaluated every 6 months or earlier to 
determine whether they had developed probable AD-type dementia according 
to the NINCDS-ADRDA group criteria [17].  
 
STATISTICS  
 All statistic tests were performed with the SPSS statistical package. Data 
derived from  metabolite concentration and brain volumes were included in a 
statistical model alongside demographic and clinical variables. In order to 
minimize the risk of obtaining results related with macroscopic variability of 
the data (for example due to differences between males and females), all 
volumes were normalized by the total intracranial volume of each participant. 
This volume was computed as the sum of the gray matter, white matter and the 
cerebrospinal fluid. As age was statistically different between groups of 
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converters and non-converters (F=8.34; p=0.006), it was included as a covariate 
of interest in the model. Different tests were then performed to identify the 
automated measurements that best discriminated both groups of patients. For 
the ANOVA test, the assumptions of normality and homoscedasticity were 
tested. Homoscedasticity was tested by inspecting the Q-Q plots and by 
carrying out a Levene test. The Kolmogorov-Smirnov test was used to check the 
normality of the data. None of the considered variables in the study violated 
these assumptions. 
In order to determine which variable (or combination of variables) was 
the best predictor of conversion to AD, we used a Fisher Linear Discriminant 
Analysis (LDA).   Three different LDA classifiers were tested, including a 
classifier with only variables from spectroscopy, a classifier with volumetric 
variables and a classifier with both, spectroscopic and volumetric 
measurements. All Fisher LDA classifiers were constructed and evaluated using 
a cross-validation strategy. 
 
RESULTS 
The ANCOVA model that included the brain volumetric measures after 
normalizing the values by the total intracranial volume showed that the most 
significant variable was the volume of the third ventricle (F= 4.382, p= 0.042). 
With spectroscopy we found statistically significant variables for converters and 
non-converters: myo-inositol in occipital cortex (F= 6.332, p= 0.016); and the 
glutamate/creatine ratio (F=4.178, p=0.047) and glutamate + glutamine (Glx) in 
the ventral posterior cingulate cortex (F= 4.128, p= 0.049) (Table 2). Volume 
measurements are given in table 3. 
After the individual evaluation of each variable using an ANCOVA 
approach, a LDA analysis was applied to determine which combination of 
variables is the best predictor for converting to AD. Considering the brain 
volumetry assessment, the following variables represented the greatest 
percentages of correct prediction: 3rd ventricle, entorhinal cortex and total 
white matter. The classifier constructed with these three variables predicted 
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conversion to probable AD at 46.67% sensitivity and 90.91% specificity, with a 
positive predictive value of 70.00% and a negative predictive value of 78.95%. 
The cross-validated accuracy of classification was 77.08%. myo-inositol in 
occipital cortex, glutamate/creatine ratio and glutamate + glutamine (Glx) in 
the posterior cingulate cortex predict conversion to probable AD at 46.15% 
sensitivity and 90.63% specificity, with a positive predictive value of 66.67% 
and a negative predictive value of 80.56%. The cross-validated accuracy of 
classification was 77.78%. Finally a unique LDA classifier including 
spectroscopic and volumetric variables (the same as in the previous single-
modality LDA classifiers) was computed, achieving a prediction to probable 
AD at 38.46% sensitivity and 87.50% specificity, with a positive predictive value 
of 55.56%, a negative predictive value of 77.78% and an overall accuracy of 
73.33%. The three proposed classifiers were also tested with the receiver 
operator characteristic (ROC) method, showing an area under the curve (AUC) 
of 0.78 for the volumetric classifier, of 0.81 for the spectroscopic classifier and of 
0.78 for the combined classifier (Fig. 2). 
 
DISCUSSION 
 In our study, we have found that baseline third ventricle volume, Myo-
inositol in occipital cortex, the Glutamate/Creatine ratio, and Glutamate + 
Glutamine (Glx) levels in the posterior cingulate cortex in amnestic MCI predict 
with high risk of early conversion to AD in comparison with non-converters.   
On the light of these results, it seems  that MRS has more influence on 
the variable conversion to Alzheimer than volumetry (especially Myo-inositol 
in occipital cortex, the Glutamate/Creatine ratio (Glu/Cr), and Glutamate + 
Glutamine (Glx) levels in the posterior cingulate cortex). In the case of using a 
standardized  total intracranial volume (TIV) and covariant age data, the only 
anatomical area showing a significant relationship with the variable  conversion 
was the third ventricle volume.  
With regard to MRS measurements, the myo-inositol in the occipital 
cortex + Glx in the posterior cingulate cortex, predicted with high specificity but 
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low sensitivity the conversion of MCI to probable Alzheimer's disease. It is 
generally observed that the negative predictive value is quite high but the 
positive predictive value is low.  
Several studies have shown the usefulness of 1H MRS in the early 
detection of  AD [13,15, 25-27]. 1H MRS has also detected biochemical abnormalities 
preceding brain atrophy and cognitive decline [28].  None of them included the 
levels of glutamate as predictor. In this study the accuracy of prediction of MRS 
was lower than in our two previous studies [13, 15] and comparable to volumetry, 
however the sample size is smaller and the follow-up period is shorter. The 
combination of MRS and volumetry was not superior to these techniques used 
individually. 
Structural neuroimaging has also been validated as a tool to  detect and 
monitor progression  of  AD. Tissue volumes in the central nervous system, and 
in particular changes in volume over time, are sensitive markers of  disease 
progression. Manual segmentation to measure the hippocampal volume is 
recognized as the gold standard [29]. It has been found that atrophy of mesial 
temporal structures, such as the hippocampus and entorhinal cortex is 
predictive of progression to AD [30]. Using semi-automated segmentation 
threshold track, Jack et al. described a sensitivity of 82% and 80% specificity for 
discriminating AD patients in the control group in a study of 220 individuals 
[31]. Serial volumetric measurements in the prediction of AD and in evaluating 
the effectiveness of therapeutic regimens in high risk populations, particularly 
those with MCI, were also described. A study of 129 patients indicated that the 
hippocampal volume within 3 years follow-up revealed atrophy rates 10 times 
higher in patients with mild or moderate dementia compared with normal 
controls [4]. Another study found that rates of percentage reduction in brain 
volume, ventricles, hippocampus and temporal horn are more significant in 
patients with MCI who develop dementia compared to those who remained 
stable (32). Structural MRI alone has also proven insufficient to predict early 
AD and additional biomarkers are needed in combination to make reliable 
predictions in MCI (33). Myo-inositol reflects glial activation or 
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neuroinflammation associated with neuronal degeneration, and it is a sensitive 
marker reflecting pathological changes in MCI and AD [25, 34]. Kantarci et al [35] , 
studied subjects with microtubule-associated protein (MAPT) mutations. Their 
results indicated that the MI/Cr ratio, a possible index of glial activation, 
precedes the decrease of NAA/Cr, a neuronal integrity and hippocampal 
atrophy. 
When analysing metabolite levels in the whole sample while controlling 
for age and gender, we observed that all metabolites were correlated with age. 
N-acetylaspartate, glutamate and glutamate+glutamine and their ratios to 
creatine showed a negative correlation (increase in age with a decrease in 
metabolite levels and vice versa), while the remaining metabolites, such as 
myo-inositol and choline, show a direct correlation.  A decrease in glutamate 
and glutamate+glutamine over time, which is associated with a certain 
cognitive deterioration, was found in Alzheimer´s Disease [36] . Decreased levels 
of N-acetylaspartate (NAA) or N-acetylaspartate/creatine ratios (NAA/Cr) are 
the most common finding reported in subjects with AD and MCI [37-39], although 
alterations in other metabolites including myo-inositol [40] and glutamate [41] are 
also found. Glutamate levels have been studied on fewer occasions in MCI and 
AD. We previously demonstrated that glutamate levels are lower in AD and 
MCI than in healthy controls in the posterior cingulate gyrus [36, 42].  
Additional longitudinal studies showed valuable results with MRS. In a 
large cohort of 151 MCI patients (most of them being of amnestic type) 
followed-up for 3 years, MRS was individually predictive of conversion to 
dementia but the accuracy of prediction improved when magnetic resonance 
spectroscopy was used in combination with hippocampal volumetry and the 
presence of cortical infarctions [43]. The value of proton magnetic resonance 
spectroscopy as a biomarker was assessed ante-mortem in a single study with 
54 patients ranging from low to high likelihood of having AD and who 
underwent autopsy. Decreases in N-acetylaspartate/creatine and increases in 
myo-inositol/creatine ratios in the posterior bilateral cingulate gyrus correlated 
with higher postmortem Braak neurofibrillary tangle staging [16].  
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  There are some caveats that influence metabolite measurements, such as 
magnetic field heterogeneity and cerebrospinal fluid (CSF), spatial resolution, 
signal-to-noise ratio, contrast-to-noise ratio contamination and artifacts. With 
the modern 3T scanners with smaller voxel analysed have overcome these 
limitations. Pitfalls in MRS can be minimised using automated and standard 
protocols. Given that the spectral patterns are well known, minor artifacts are 
relatively easy to identify.  
With regard to other neuroradiological and biological predictors, SPECT 
has shown to be inferior to MRI techniques. According to the results of the 
largest ever cohort the overal accuracy was only 58%44.  FDG-PET and amyloid-
binding radiotracer PET are of superior value but both are costly and not 
widely available38. Protein tau and Beta42 amyloid peptide levels in the CSF are 
excellent predictors of conversion to AD45 but they need lumbar puncture. 
APOE genotype is also useful but only in terms of specificity15,38. Therefore 
there is no clear consensus on what is the best biomarker of early AD. 
In conclusion, both 1HMRS and brain volumetry are markers separately 
of cognitive decline and transition from MCI to AD. Given the high prevalence 
of AD and the predictive values below 80%, these techniques ar far from being 
useful as routine procedures in the clinical setting.  
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Table 1. Demographic variables and scales scores in the cohort of 48 patients 
with mild cognitive impairment 
_______________________________________  
Mean SD Significance  
Age, years 
Female 
Male 
73.7 (7.1) 
75.2 (6.7) 
F=0.51; P=0.476 
Gender 
(female/male) 
30/18 
Gender and 
volumetry: GM 
and WM 
F=28.14 ; P<0.001 
F=29.79; P=<0.001 
Age and GM r= -0.40; P=0.005 
Convert/Not 
convert 
9/21 
6/12 
F=8.34; P=0.006 
MEC 28.3 (3.1) 
Blessed 
Dementia 
Rating Scale 
2.6 (0.9) 
Memory 
Impairment 
Screen 
2.3 (1.6) 
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Rey Auditory 
Verbal 
Learning test 
3.2 (2.6)  
Mean follow-
up months 
36 (6.7)  
 
 
 
 
  Table 2. a) ANCOVA performed on morphometric variables (normalized by 
Intracranial Volume Total values). Significant variables. 
Localization F P 
Third ventricle 4.382 0.042 
 
 
Table 2. b) ANCOVA on spectral data. Significant variables. 
 
Localization and 
metabolites 
F P 
Occipital Myo-inositol 6.332 0.016 
Post Cingulate Glu/Cr 4.178 0.047 
Post Cingulate Glx  4.128 0.049 
Glu: glutamate; Cr: creatine; Glx: glutamate+glutamine; Post: posterior 
 
TABLE 3. Relative volumes (in %): 
 Group Mean Standard Deviation   
Total Gray Matter Non-converters 53,383 2,976 
  Converters 52,593 2,373 
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Total White Matter Non-converters 43,330 2,650 
Converters 42,582 2,052 
Lateral Ventricle Right Non-converters 1,422 0,762 
Converters 2,074 0,965 
Lateral Ventricle Left Non-converters 1,523 0,784 
Converters 2,335 0,824 
Fourth Ventricle Non-converters 0,151 0,067 
Converters 0,167 0,058 
Third Ventricle Non-converters 0,192 0,055 
Converters 0,249 0,053 
Frontal Lobe Right Non-converters 6,426 0,592 
Converters 6,315 0,317 
Frontal Lobe Left Non-converters 6,336 0,536 
Converters 6,186 0,468 
Temporal Lobe Right Non-converters 4,279 0,319 
Converters 4,208 0,294 
Temporal Lobe Left Non-converters 4,262 0,340 
Converters 4,111 0,350 
Parietal Lobe Right Non-converters 4,640 0,311 
Converters 4,440 0,343 
Parietal Lobe Left Non-converters 4,480 0,354 
Converters 4,340 0,407 
Occipital Lobe Right Non-converters 2,017 0,212 
Converters 1,970 0,142 
Occipital Lobe Left Non-converters 1,997 0,234 
Converters 1,914 0,214 
Cingulated Gyrus Right Non-converters 0,788 0,116 
Converters 0,753 0,098 
Cingulated Gyrus Left Non-converters 0,802 0,131 
Converters 0,770 0,070 
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Thalamus Right Non-converters 0,614 0,068 
  Converters 0,606 0,056 
Thalamus Left Non-converters 0,664 0,065 
  Converters 0,663 0,073 
Caudate Nucleus Right Non-converters 0,334 0,046 
  Converters 0,351 0,059 
Caudate Nucleus Left Non-converters 0,329 0,041 
  Converters 0,337 0,057 
Putamen Right Non-converters 0,442 0,067 
  Converters 0,446 0,056 
Putamen Left Non-converters 0,477 0,055 
  Converters 0,486 0,067 
Globus Pallidus Right Non-converters 0,144 0,021 
  Converters 0,147 0,023 
Globus Pallidus Left Non-converters 0,146 0,018 
  Converters 0,155 0,020 
Hippocampus Right Non-converters 0,377 0,053 
  Converters 0,351 0,075 
Hippocampus Left Non-converters 0,364 0,059 
  Converters 0,324 0,060 
Amygdala Right Non-converters 0,141 0,025 
  Converters 0,137 0,025 
Amygdala Left Non-converters 0,134 0,027 
  Converters 0,121 0,023 
Cerebellum Gray 
Matter Right 
Non-converters 5,103 0,459 
  Converters 5,293 0,513 
Cerebellum Gray 
Matter Left 
Non-converters 4,999 0,442 
  Converters 5,176 0,404 
Cerebellum White Non-converters 1,390 0,218 
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Matter Right 
  Converters 1,394 0,212 
Cerebellum White 
Matter Left 
Non-converters 1,332 0,178 
  Converters 1,302 0,173 
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Figure 1. Voxel placement  
1a. Sagittal and occipital T1-weighted magnetic resonance imaging with the 
voxel placed in the ventral posterior cingulate gyrus and inferior precuneus (a) 
and occipital cortex (b)  
Figure 1b Example of spectrum with the following peaks: mI, myo-inositol; 
Cho, choline compounds; Cr, creatine; Glx, glutamate + glutamine + GABA; 
NAA, N-acetylaspartate; ppm, parts per million (c,d). 
Figure 2. Baseline brain morphometry and spectroscopy as a predictor of 
conversion from mild cognitive impairment to probable Alzheimer’s disease.  
ROC curves. 
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Figure 1a 
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Figure 2 
